1. European Medicines Agency E. Orphan designation. 2011 [cited 2011 4th February]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240ce&jsenabled=true
2. Clinicaltrials.gov. 2010; Available from: http://clinicaltrials.gov/ct2/results?term=Huntington%27s+disease&cond=%22Huntington+Disease%22.
3. Therapeutic interventions for symptomatic treatment in Huntington’s disease;Mestre;Cochrane Database Syst Rev,2009
4. Therapeutic interventions for disease progression in Huntington’s disease;Mestre;Cochrane Database Syst Rev,2009
5. Public summary of opinion on orphan designation: Lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington’s disease;European Medicines Agency E,2011